Olmesartan Medoxomil E Amlodipina Teva (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil E Amlodipina Teva, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage high blood pressure in adult patients. GNH USA supplies Olmesartan Medoxomil E Amlodipina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil E Amlodipina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil / Amlodipine combines two antihypertensive agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone.

- Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - Chronic kidney disease with hypertension: helps achieve target blood‑pressure goals to slow renal decline. - Heart failure with reduced ejection fraction (as adjunct therapy): contributes to afterload reduction and symptom control. - Post‑myocardial infarction hypertension: assists in secondary prevention by maintaining optimal blood pressure. - Elderly patients with isolated systolic hypertension: offers effective systolic pressure lowering with a favorable tolerability profile.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after the first doses. - Flushing: transient warmth and reddening of the skin. - Fatigue: general feeling of tiredness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue or airway. - Severe hypotension: symptomatic low blood pressure requiring medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Acute kidney injury: sudden decline in renal function. - Cardiac arrhythmias: irregular heart rhythms. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Before initiating therapy, clinicians should evaluate patient history and comorbid conditions.

- Renal impairment: adjust dose and monitor serum creatinine. - Hepatic disease: use with caution; monitor liver function tests. - Electrolyte disturbances: check potassium and sodium levels regularly. - Concomitant diuretics: assess for additive blood‑pressure lowering effects. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Olmesartan Medoxil / Amlodipine may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal impairment. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine plasma concentrations. - Lithium: may increase lithium levels, risking toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Potassium‑sparing diuretics or supplements: monitor serum potassium. - Antidiabetic agents: possible enhancement of glucose‑lowering effect. - Rifampicin: may reduce amlodipine concentrations, requiring dose adjustment.